

Nationwide Alert on Injectable Drugs Prepared by Urgent Care Pharmacy (11/02)

DIS has learned that the Food and Drug Administration (FDA) has announced a nationwide alert concerning all injectable drugs prepared by Urgent Care Pharmacy of Spartanburg, South Carolina, based on the lack of assurance that their products are sterile. Non-sterility of injectable products can represent a serious hazard to health that could lead to life-threatening injuries and death. FDA inspection of Urgent Care's facility revealed the firm failed to have adequate controls to ensure necessary sterility, including the absence of appropriate testing for potency and sterility prior to distribution. At the present time, based on limited information, the FDA is aware that Urgent Care has distributed the following injectable drugs to physicians, hospitals, clinics and consumers in Connecticut, Illinois, Indiana, Kentucky, Louisiana, Massachusetts, Mississippi, New Hampshire, North Carolina, South Carolina, and Virginia:



Baclofen
Betamethasone
Bimix 30:1 (Phentolamine mesylate/papaverine)
Clonidine
Estradiol
Hydromorphone HCl
Fentanyl
Methylprednisolone acetate
Morphine Sulfate/Bupivacaine
Papaverine HCl
Super Trimix (Papaverine HCl/phentolamine mesylate/prostaglandin)
Testosterone cypionate
Testosterone/Estradiol

Oral surgeons and others who might be using the above injectable medications should examine their drug supplies for any Urgent Care products. According to the FDA, Urgent Care injectables are labeled as URGENT CARE PHARMACY 2500 WINCHESTER PLACE, STE. 106, SPARTANBURG, SC 29301, (800) 692-8982. Users should also notify the FDA of any complaints or problems associated with these products by contacting MedWatch, the FDA's voluntary reporting program, by phone at (800) FDA-1088 or on line at <http://www.fda.gov/medwatch/how.htm>. For additional information, the FDA can be contacted at (888) INFO-FDA.